Research press release


Nature Communications

Cancer: Cervical cells may aid the detection of ovarian and breast cancers

子宮頸がんの検診で採取された細胞を卵巣がんの特定に使用できる可能性があると示唆する論文が、Nature Communications に掲載される。また、別の論文では、定期検診で採取された子宮頸部細胞を用いて、乳がんの存在を判定できる可能性のある検査法が開発されたことが報告された。いずれの知見も小規模な女性コホートから得られたものだが、卵巣がんと乳がんの早期発見を可能にするかもしれない。


今回、Martin Widschwendterたちは、卵巣にがんのある女性242人と卵巣にがんのない女性869人からなるコホートから採取した子宮頸部細胞検体を用いた。Widschwendterたちは、これらの検診検体において1万4000のエピジェネティック変化(DNA自体は変化させずに遺伝子発現パターンを変化させる分子修飾)を測定した。その結果、卵巣がんの存在を特定または予測するために使用できる可能性のあるDNAメチル化シグネチャーが特定された。このコホートでは、メチル化シグネチャーを用いることで、50歳未満の卵巣がんの女性の71.4%と50歳以上の卵巣がんの女性の54.5%において、75%の特異性で卵巣がんが特定された。この知見は、さらに別の女性コホート(卵巣がん患者47人と非卵巣がん患者227人)で検証され、検査スコアの高い女性は卵巣がんリスクが高い可能性があることが明らかになった。



Cells collected during cervical cancer screening tests could be used to identify ovarian cancers, suggests a paper published in Nature Communications. A second paper reports the development of a test using cervical cells collected from routine screenings, which may be able to determine the presence of breast cancer. The findings, in small cohorts of women, may enable the earlier detection of both cancers.

Ovarian cancer is responsible for the largest proportion of deaths associated with gynaecological cancers. Currently, 75% of ovarian cancers are diagnosed at a late stage, when the tumours have spread, and being able to detect the disease earlier may improve treatment outcomes. Breast cancer is the most common cancer in females and is usually detected using mammography followed by a biopsy. Previous research has suggested that DNA changes could be used to predict the risk of developing these cancers.

Martin Widschwendter and colleagues used cervical cell samples collected from a cohort of 242 women with and 869 without ovarian cancer. The authors measured 14,000 epigenetic changes (molecular modifications that alter patterns of gene expression without the DNA itself being altered) in the screening samples. They identified a DNA methylation signature that could be used to identify or predict the presence of ovarian cancer. In the cohort, the methylation signature allowed the authors to identify 71.4% of women under 50 years of age and 54.5% of women over 50 years of age with ovarian cancers with 75% specificity. The findings were further validated in an additional cohort of women, where 47 had ovarian cancer and 227 did not, and found that women with higher scores may have an increased risk of ovarian cancer.

In a second study, the authors initially analysed epigenetic changes in cervical cell samples from 329 women with breast cancer with a poor prognosis and 869 women without breast cancer. They found they were able to identify women with breast cancer based on an epigenetic signature. They confirmed this finding in a smaller set of samples from 113 breast cancer patients and 225 women without breast cancer.

The authors indicate their findings suggest that using epigenetic signatures may aid in the detection of these cancers. However, the authors conclude that further research and large-scale prospective clinical trials are needed to determine whether these tests could predict the likelihood of woman developing either of these cancers.

doi: 10.1038/s41467-021-27918-w

「Nature 関連誌注目のハイライト」は、ネイチャー広報部門が報道関係者向けに作成したリリースを翻訳したものです。より正確かつ詳細な情報が必要な場合には、必ず原著論文をご覧ください。

メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週最新のNature 関連誌のハイライトを皆様にお届けいたします。